Free Trial
→ A new rule goes live in July — and the banks are quietly cashing in (From American Alternative) (Ad)
NYSEAMERICAN:AZTR

Azitra 5/9/2024 Earnings Report

Azitra logo
$0.25 -0.02 (-5.92%)
Closing price 06/20/2025 04:10 PM Eastern
Extended Trading
$0.25 +0.00 (+0.61%)
As of 06/20/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
ProfileEarnings History

Azitra EPS Results

Actual EPS
-$4.50
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Azitra Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Azitra Announcement Details

Quarter
Date
5/9/2024
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Azitra's next earnings date is estimated for Monday, August 11, 2025, based on past reporting schedules.

Conference Call Resources

Azitra Earnings Headlines

Azitra, Inc.: Azitra Reports Promising Safety Data from Phase 1b Trial in Netherton Syndrome
June 17, 2025 | finanznachrichten.de
Azitra Reports Promising Safety Data from Phase 1b Trial in Netherton Syndrome
June 17, 2025 | prnewswire.com
Trump Made a Deal. Your Retirement Could Still Be in Danger.
America is still barreling toward a financial cliff. This isn't political. It's mathematical. And no trade deal can undo decades of economic rot. The smart money is moving to gold, fast. And Lear Capital is making it simple to protect your savings before the next crash hits.
June 21, 2025 | Lear Capital (Ad)
Azitra, Inc. Announces Presentation at the 2025 BIO International Convention
June 10, 2025 | prnewswire.com
Azitra, Inc. Announces Presentation at ASCO 2025 Highlighting Clinical Trial Investigating ATR-04 for EGFRi-Associated Rash
May 28, 2025 | prnewswire.com
AZTR: ATR-04 Trial to Dose 1st Patient Mid-2025
May 21, 2025 | finance.yahoo.com
See More Azitra Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Azitra? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Azitra and other key companies, straight to your email.

About Azitra

Azitra (NYSEAMERICAN:AZTR), an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. It has a collaboration with Bayer. The company was incorporated in 2014 and is based in Branford, Connecticut.

View Azitra Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles